Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)

/PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to...

Related Keywords

Germany ,United States ,New Jersey ,Washington ,Cambridge ,Cambridgeshire ,United Kingdom ,Heidelberg ,Baden Wüberg ,Canada ,Denver ,Colorado ,Americans ,Canadian ,American ,Christian Roesky ,Novaliq Gmb ,Josephc Papa ,Prnewswire Bausch ,Instagram ,Linkedin ,Twitter ,Drug Administration ,Lomb Corporation ,Exchange Commission ,American Society Of Cataract ,Gmbh Co ,Facebook ,Association For Research ,Novaliq Inc ,Bausch Health ,Health Sciences ,Novaliq Gmbh ,New Drug Application ,American Society ,Refractive Surgery ,Hopp Biotech ,Canadian Securities Administrators ,Dry Eye ,Eye Products Market Report ,Randomized Clinical Study ,Assess Efficacy ,Bausch Lomb Corporation ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,